4. Primary Results of NRG Oncology/NSABP B-35: <br />A Clinical Trial of Anastrozole vs Tamoxifen in <br />Postmenopausal Patients with DCIS
Presented By Richard Margolese at 2015 ASCO Annual Meeting
14. CALGB 40503 (Alliance)/CTSU 40503/NCT00601900<br /><br />Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive
(HR+)<br />Advanced Breast Cancer
Presented By Maura Dickler at 2015 ASCO Annual Meeting
15. Study Design - CALGB (Alliance) 40503<br />Multicenter Randomized Phase III Trial of 1st-line Letrozole +/- Bev
Presented By Maura Dickler at 2015 ASCO Annual Meeting
20. Phase III Trials Endocrine Therapy +/- Bevacizumab (open-label)
Presented By Joseph Sparano at 2015 ASCO Annual Meeting
21. Abstract LBA502 <br /><br /> A Double Blind Phase 3 Trial of Fulvestrant With or Without Palbociclib in Pre- and Post-menopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast
Cancer That Progressed on Prior Endocrine Therapy<br />(PALOMA3 Study)
Presented By Nicholas Turner at 2015 ASCO Annual Meeting
38. L Gianni, T Pienkowski, Y-H Im, L-M Tseng, M-C Liu, A Lluch, <br />E StarosĆawska, J de la Haba-Rodriguez, S-A Im, JL Pedrini, B Poirier, <br />P Morandi, V Semiglazov, V Srimuninnimit, GV Bianchi, <br />V
McNally, H Douthwaite, G Ross, P Valagussa
Presented By Luca Gianni at 2015 ASCO Annual Meeting
39. NeoSphere: Phase 2 Neoadjuvant HER2+ Study
Presented By Shanu Modi at 2015 ASCO Annual Meeting
41. PFS by tpCR: all treatment arms combined, <br />ITT population
Presented By Luca Gianni at 2015 ASCO Annual Meeting
42. Lower pCR Rates for HR+ HER2+ BC
Presented By Shanu Modi at 2015 ASCO Annual Meeting
43. <br />Oral Abstract Session: <br />Breast CancerâHER2/ER<br /><br />Substantial efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early
breast cancer: <br />WSG-ADAPT HER2+/HR+ phase II trial<br />
Presented By Nadia Harbeck at 2015 ASCO Annual Meeting
44. ADAPT HER2+/HR+: <br />Neoadjuvant Phase 2 Trial
Presented By Shanu Modi at 2015 ASCO Annual Meeting
45. Phase III, randomized study of trastuzumab emtansine ± pertuzumab vs trastuzumab + taxane for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study
Presented By Paul Ellis at 2015 ASCO Annual Meeting
50. Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3 randomized, placebo-controlled trial (ExteNET)
Presented By Arlene Chan at 2015 ASCO Annual Meeting
57. Results from a Phase 2 Study of Enzalutamide, an Androgen Receptor Inhibitor, in Advanced AR+ Triple-Negative Breast Cancer (MDV3100-11)
Presented By Tiffany Traina at 2015 ASCO Annual Meeting
58. Enzalutamide is a Potent Inhibitor of AR Signaling
Presented By Tiffany Traina at 2015 ASCO Annual Meeting
59. AR Signaling and Triple-Negative Breast Cancer
Presented By Tiffany Traina at 2015 ASCO Annual Meeting
68. Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC) (abstr 1005)
Presented By Nadine Tung at 2015 ASCO Annual Meeting